Suppr超能文献

髓过氧化物酶、五聚素-3和可溶性尿激酶型纤溶酶原激活物受体测定在中度颈动脉狭窄患者中的意义

Significance of myeloperoxidase, pentraxin-3 and soluble urokinase plasminogen activator receptor determination in patients with moderate carotid artery stenosis.

作者信息

Ruzanovic Ana, Saric-Matutinovic Marija, Milinkovic Neda, Jovicic Snezana, Dimic Andreja, Matejevic David, Kostic Ognjen, Koncar Igor, Ignjatovic Svetlana

机构信息

Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.

University Clinical Center of Serbia, Clinic for Vascular and Endovascular surgery, Belgrade, Serbia.

出版信息

Scand J Clin Lab Invest. 2024 Nov-Dec;84(7-8):486-492. doi: 10.1080/00365513.2024.2422404. Epub 2024 Nov 7.

Abstract

We investigated serum concentrations of specific inflammatory parameters in patients with significant carotid artery stenosis (CAS) of 50-99%, with an additional focus on patients with moderate stenosis (50-69%), in terms of both symptomatic status and plaque morphology, to determine whether there are certain parameters that can be associated with plaque instability before the progression of CAS to a high degree. The study included 119 CAS patients, 29 of whom had moderate stenosis, and 46 controls. Ultrasonography of the carotid arteries was performed using color flow Doppler and B-mode duplex ultrasound, and serum inflammatory parameters were measured using commercially available enzyme immunoassays. When comparing patients with 50-99% stenosis, only serum amyloid A (SAA) was higher in symptomatic patients, while in the group of patients with 50-69% stenosis, myeloperoxidase (MPO) was higher and pentraxin-3 (PTX-3) was lower in symptomatic compared to asymptomatic patients, and soluble urokinase plasminogen activator receptor (suPAR) was higher in patients with carotid plaque of unstable compared to stable morphology. Our results suggest that the importance of different inflammatory parameters in patients with moderate CAS is not the same as in CAS patients in general, and therefore their separate investigation in patients with high and moderate stenosis may be beneficial. SAA has the potential to be further considered in research to predict CAS symptom risk. There is a possibility that MPO and PTX-3 play a role in the development of CAS symptoms originating from less stenotic plaques and that suPAR is involved in the destabilisation of such plaques.

摘要

我们研究了颈动脉狭窄程度为50%-99%的显著颈动脉狭窄(CAS)患者血清中特定炎症参数的浓度,特别关注中度狭窄(50%-69%)的患者,从症状状态和斑块形态两方面进行研究,以确定在CAS进展到高度狭窄之前,是否存在某些与斑块不稳定相关的参数。该研究纳入了119例CAS患者,其中29例为中度狭窄患者,以及46名对照者。使用彩色多普勒血流成像和B型双功超声对颈动脉进行超声检查,并使用市售酶免疫测定法测量血清炎症参数。在比较狭窄程度为50%-99%的患者时,仅症状性患者的血清淀粉样蛋白A(SAA)较高;而在狭窄程度为50%-69%的患者组中,有症状患者的髓过氧化物酶(MPO)较高,五聚素-3(PTX-3)较低,与无症状患者相比,不稳定形态颈动脉斑块患者的可溶性尿激酶型纤溶酶原激活物受体(suPAR)较高。我们的结果表明,中度CAS患者中不同炎症参数的重要性与一般CAS患者不同,因此对高度和中度狭窄患者分别进行研究可能是有益的。SAA在预测CAS症状风险的研究中有可能被进一步考虑。MPO和PTX-3有可能在起源于狭窄程度较轻斑块的CAS症状发展中起作用,而suPAR参与此类斑块的不稳定过程。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验